RenovoRx Files to Sell 8.44M Shares of Common Stock
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 4 days ago
0mins
Should l Buy RNXT?
RenovoRx files to sell 8.44M shares of common stock for holders
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy RNXT?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on RNXT
Wall Street analysts forecast RNXT stock price to rise
4 Analyst Rating
4 Buy
0 Hold
0 Sell
Strong Buy
Current: 1.005
Low
3.00
Averages
5.63
High
12.50
Current: 1.005
Low
3.00
Averages
5.63
High
12.50
About RNXT
RenovoRx, Inc. is a clinical and a commercial biopharmaceutical company. Its lead product RenovoCath a local drug delivery device, targeting high unmet medical needs. RenovoRx’s patented Trans-Arterial Micro-Perfusion (TAMP) therapy platform is designed to ensure targeted therapeutic delivery across the arterial wall near the tumor site to bathe the target tumor. RenovoRx’s novel approach to targeted treatment offers the potential for increased safety, tolerance, and improved efficacy, and to transform the lives of cancer patients by providing innovative solutions to enable targeted delivery of diagnostic and therapeutic agents. In addition to the RenovoCath device, RenovoRx is also evaluating the novel Phase III drug-device combination oncology product candidate (intra-arterial gemcitabine, known as IAG). The combination of intra-arterial infusion of chemotherapy, gemcitabine, and the RenovoCath device is being evaluated for the treatment of locally advanced pancreatic cancer.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
RenovoRx Named 10th Most Innovative Medical Device Company by Fast Company
- Innovative Company Ranking: RenovoRx has been recognized by Fast Company as the 10th most innovative medical device company in 2026, highlighting its innovation capabilities in cancer treatment and enhancing its brand image in the industry.
- Commercialization Progress: In 2025, RenovoCath generated approximately $1.1 million in sales, indicating a growing market penetration in cancer centers and increasing physician recognition of its targeted drug delivery technology.
- Market Potential Assessment: RenovoRx estimates that the initial total addressable market for RenovoCath is around $400 million, with the potential to reach multi-billion dollar sales opportunities as the platform expands into additional solid tumor indications, further solidifying its market position.
- Technology Platform Advantage: The Trans-Arterial Micro-Perfusion (TAMP™) therapy enabled by RenovoCath allows for targeted drug delivery, potentially reducing treatment toxicities and improving efficacy, aligning with the company's mission to enhance the quality of life for cancer patients.
See More
RenovoRx Reports Wider Net Loss Despite Revenue Growth in 2025
- Financial Performance: RenovoRx's net loss for 2025 widened to $11.2 million from $8.8 million last year, despite revenue growth from $43,000 to $1.12 million, indicating initial market acceptance of its products.
- Cash Position: As of December 31, 2025, RenovoRx had approximately $7.02 million in cash and cash equivalents, with recent private placement proceeds providing around $13 million to support upcoming key milestones.
- Clinical Trial Progress: The company is advancing its Phase III TIGeR-PaC clinical trial evaluating intra-arterial delivery of gemcitabine via the RenovoCath device, with plans to complete enrollment of 114 patients by mid-2026.
- Market Potential: The initial total addressable market for RenovoCath as a stand-alone device is estimated at $400 million, with the CEO asserting that the company has the necessary funding and infrastructure to drive execution towards critical milestones.
See More
RenovoRx Reports Strong 2025 Revenue Growth and Expansion Plans
- Significant Revenue Growth: RenovoRx reported over $1.1 million in revenue for 2025, indicating strong initial adoption of RenovoCath, with 2026 revenue guidance expected to range between $3 million and $4 million, showcasing the company's rapid growth potential in the cancer treatment market.
- Network Expansion: As of February 2026, RenovoRx has established operations at 12 active commercial cancer centers, with plans to expand this number to approximately 36 by year-end 2026, reflecting a proactive strategy to enhance market coverage and customer base.
- Funding Support: The company successfully closed an oversubscribed private placement, raising approximately $10 million to support commercial expansion and clinical development, which enhances its financial flexibility in a competitive healthcare market.
- Clinical Trial Progress: The TIGeR-PaC trial has randomized 104 patients, with a goal of 114, expected to complete soon, facilitating the transition of related centers to commercial use and further driving revenue growth.
See More
RenovoRx Reports FY 2025 Financial Results with Private Placement
- Financial Performance: RenovoRx reported a FY 2025 GAAP EPS of -$0.32, aligning with expectations, yet revenue of $1.12 million fell short by $0.18 million, indicating challenges in revenue growth.
- Cash Position: As of December 31, 2025, RenovoRx had approximately $7.0 million in cash and cash equivalents, reflecting liquidity pressures in maintaining operational stability.
- Financing Activity: Following the fiscal year-end, RenovoRx closed a private placement on March 20, 2026, raising gross proceeds of $10 million and net proceeds of $9.2 million, which will help strengthen the company's balance sheet.
- Market Reaction: Despite the financing improving financial conditions, the failure to meet revenue expectations may negatively impact investor confidence, leading to potential stock price volatility.
See More
RENOVORX REPORTS FY OPERATING EXPENSES OF USD 13.306 MILLION
- Financial Overview: RenovorX reported operating expenses amounting to USD 13.306 million.
- Expense Breakdown: The financial details indicate a significant investment in operational activities.
See More
RENOVORX REPORTS FY NET LOSS OF USD 11.168 MILLION
- Company Overview: Renovorx FY reported a net income of USD 11.168 million.
- Financial Performance: The financial results indicate a positive performance for the fiscal year.
- Market Impact: The reported income may influence investor confidence and market perception of Renovorx.
- Future Outlook: Analysts may look for further developments and projections based on this financial performance.
See More
RenovoRx Named 10th Most Innovative Medical Device Company by Fast Company
- Innovative Company Ranking: RenovoRx has been recognized by Fast Company as the 10th most innovative medical device company in 2026, highlighting its innovation capabilities in cancer treatment and enhancing its brand image in the industry.
- Commercialization Progress: In 2025, RenovoCath generated approximately $1.1 million in sales, indicating a growing market penetration in cancer centers and increasing physician recognition of its targeted drug delivery technology.
- Market Potential Assessment: RenovoRx estimates that the initial total addressable market for RenovoCath is around $400 million, with the potential to reach multi-billion dollar sales opportunities as the platform expands into additional solid tumor indications, further solidifying its market position.
- Technology Platform Advantage: The Trans-Arterial Micro-Perfusion (TAMP™) therapy enabled by RenovoCath allows for targeted drug delivery, potentially reducing treatment toxicities and improving efficacy, aligning with the company's mission to enhance the quality of life for cancer patients.
See More
RenovoRx Reports Wider Net Loss Despite Revenue Growth in 2025
- Financial Performance: RenovoRx's net loss for 2025 widened to $11.2 million from $8.8 million last year, despite revenue growth from $43,000 to $1.12 million, indicating initial market acceptance of its products.
- Cash Position: As of December 31, 2025, RenovoRx had approximately $7.02 million in cash and cash equivalents, with recent private placement proceeds providing around $13 million to support upcoming key milestones.
- Clinical Trial Progress: The company is advancing its Phase III TIGeR-PaC clinical trial evaluating intra-arterial delivery of gemcitabine via the RenovoCath device, with plans to complete enrollment of 114 patients by mid-2026.
- Market Potential: The initial total addressable market for RenovoCath as a stand-alone device is estimated at $400 million, with the CEO asserting that the company has the necessary funding and infrastructure to drive execution towards critical milestones.
See More
RenovoRx Reports Strong 2025 Revenue Growth and Expansion Plans
- Significant Revenue Growth: RenovoRx reported over $1.1 million in revenue for 2025, indicating strong initial adoption of RenovoCath, with 2026 revenue guidance expected to range between $3 million and $4 million, showcasing the company's rapid growth potential in the cancer treatment market.
- Network Expansion: As of February 2026, RenovoRx has established operations at 12 active commercial cancer centers, with plans to expand this number to approximately 36 by year-end 2026, reflecting a proactive strategy to enhance market coverage and customer base.
- Funding Support: The company successfully closed an oversubscribed private placement, raising approximately $10 million to support commercial expansion and clinical development, which enhances its financial flexibility in a competitive healthcare market.
- Clinical Trial Progress: The TIGeR-PaC trial has randomized 104 patients, with a goal of 114, expected to complete soon, facilitating the transition of related centers to commercial use and further driving revenue growth.
See More
RenovoRx Reports FY 2025 Financial Results with Private Placement
- Financial Performance: RenovoRx reported a FY 2025 GAAP EPS of -$0.32, aligning with expectations, yet revenue of $1.12 million fell short by $0.18 million, indicating challenges in revenue growth.
- Cash Position: As of December 31, 2025, RenovoRx had approximately $7.0 million in cash and cash equivalents, reflecting liquidity pressures in maintaining operational stability.
- Financing Activity: Following the fiscal year-end, RenovoRx closed a private placement on March 20, 2026, raising gross proceeds of $10 million and net proceeds of $9.2 million, which will help strengthen the company's balance sheet.
- Market Reaction: Despite the financing improving financial conditions, the failure to meet revenue expectations may negatively impact investor confidence, leading to potential stock price volatility.
See More
RENOVORX REPORTS FY OPERATING EXPENSES OF USD 13.306 MILLION
- Financial Overview: RenovorX reported operating expenses amounting to USD 13.306 million.
- Expense Breakdown: The financial details indicate a significant investment in operational activities.
See More
RENOVORX REPORTS FY NET LOSS OF USD 11.168 MILLION
- Company Overview: Renovorx FY reported a net income of USD 11.168 million.
- Financial Performance: The financial results indicate a positive performance for the fiscal year.
- Market Impact: The reported income may influence investor confidence and market perception of Renovorx.
- Future Outlook: Analysts may look for further developments and projections based on this financial performance.
See More
